Results 201 to 210 of about 70,632 (244)

Malaria mosquito antimicrobial defence requires immunity and detoxification gene regulation by Lola

Insect Molecular Biology, EarlyView.
Malaria mosquito antimicrobial defence requires upregulation of lola. Attenuation of lola in the midgut of Anopheles albimanus mosquitoes inhibits the upregulation of immunity genes induced by challenge. Putative target genes of the Lola transcription factor were revealed by lola attenuation, including Cecropin‐C, Draper, PPAF2, Clip‐domain serine ...
Heidi Espadas‐Álvarez, Verónica Valverde‐Garduño   +1 more
wiley   +1 more source

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source

4‐1BBL Suppresses Anti‐Inflammatory Responses by Regulating Metabolic Reprogramming of Macrophages

Immunology, EarlyView.
4‐1BB ligand (4‐1BBL) is known to promote sustained pro‐inflammatory responses in macrophages. This study demonstrates that 4‐1BBL acts as a negative regulator of anti‐inflammatory macrophage responses. Genetic deletion or pharmacological inhibition of 4‐1BBL significantly enhanced the phosphorylation of IL‐4R‐proximal JAK1 and STAT6, elevating the ...
Young Jun Kang
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pharmacophore and docking-based virtual screening approach for the design of new dual inhibitors of Janus kinase 1 and Janus kinase 2

SAR and QSAR in Environmental Research, 2014
Janus kinase 1 and 2, non-receptor protein tyrosine kinases, are implicated in various cancerous diseases. Involvement of these two enzymes in the pathways that stimulate cell proliferation in cancerous conditions makes them potential therapeutic targets for designing new dual-targeted agents for the treatment of cancer.
Om Silakari, Haneesh Jasuja
exaly   +3 more sources

Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis

Cochrane Database of Systematic Reviews, 2015
Myelofibrosis is a bone marrow disorder characterized by excessive production of reticulin and collagen fiber deposition caused by hematological and non-hematological disorders. The prognosis of myelofibrosis is poor and treatment is mainly palliative.
Arturo J, Martí-Carvajal, Vidhu, Anand, Ivan, Solà   +2 more
openaire   +4 more sources

Molecular cloning and functional characterization of duck Janus kinase 1

Molecular Immunology, 2020
Janus kinase 1 (JAK1) is a member of JAK family of non-receptor protein tyrosine kinases that plays critical roles in transducing cytokine signals via JAK-signal transducer and activator of transcription (STAT) signaling pathway. The importance of JAK1 in innate immunity has been well-studied in mammals and fish, yet in avian remains largely unknown ...
Dejian, Liu, Huijun, Zheng, Yaqian, Li, Peng, Zhou, Hui, Jin, Rui, Luo   +5 more
openaire   +2 more sources

Mechanism of Janus kinase 3-catalyzed phosphorylation of a Janus kinase 1 activation loop peptide

Archives of Biochemistry and Biophysics, 2003
A high-affinity IL-2 receptor requires two Janus protein tyrosine kinases (JAKs) for IL-2 signal transduction: JAK1 and JAK3. Since transphosphorylation of the two kinases is presumed to occur after receptor engagement we examined the phosphorylation by recombinant JAK3 of a peptide substrate corresponding to the JAK1 activation loop (KAIETDKEYYTVKD ...
Ruixiu, Wang, Patrick R, Griffin, Eliza C, Small, James E, Thompson   +3 more
openaire   +2 more sources

Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1

Bioorganic & Medicinal Chemistry Letters, 2013
The identification of a novel fused triazolo-pyrrolopyridine scaffold, optimized derivatives of which display nanomolar inhibition of Janus kinase 1, is described. Prototypical example 3 demonstrated lower cell potency shift, better permeability in cells and higher oral exposure in rat than the corresponding, previously reported, imidazo ...
Christopher A, Hurley, Wade S, Blair, Richard J, Bull, Christine, Chang, Peter H, Crackett, Gauri, Deshmukh, Hazel J, Dyke, Rina, Fong, Nico, Ghilardi, Paul, Gibbons, Peter R, Hewitt, Adam, Johnson, Tony, Johnson, Jane R, Kenny, Pawan Bir, Kohli, Janusz J, Kulagowski, Marya, Liimatta, Patrick J, Lupardus, Robert J, Maxey, Rohan, Mendonca, Raman, Narukulla, Rebecca, Pulk, Savita, Ubhayakar, Anne, van Abbema, Stuart I, Ward, Bohdan, Waszkowycz, Mark, Zak   +26 more
openaire   +2 more sources

Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis

2013
This is the protocol for a review and there is no abstract. The objectives are as follows: To determine the clinical efficacy and safety of JAK1 and JAK2 inhibitors for treating MF generated by hematologic or non-hematologic conditions. © 2013 The Cochrane Collaboration.
Martí-Carvajal A.J., Cardona A.F., Anand V., Solà I.   +3 more
openaire   +2 more sources